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Abstract Most preterm infant formulas contain medium-
chain triacylglycerols (MCT), but the effects of MCT on
polyunsaturated fatty acid status and metabolism are con-
troversial. Thus, we studied the effects of MCT on linoleic
acid metabolism using stable isotopes. Enterally fed pre-
term infants were randomized to receive for 7 days 40% of


















C enrichment of phospholipid fatty acids were mea-
sured and tracer oxidation was monitored. Compared with
 








and higher plasma triacylglycerol contents of octanoic acid, of



























Concentrations of several polyunsaturated fatty acids in
plasma phospholipids and non esterified fatty acids were




C concentrations in phospho-
lipid n-6 fatty acids indicated no difference in the relative
conversion of linoleic to arachidonic acid.  We conclude
that oral MCT effectively reduce polyunsaturated fatty acid
 
and long chain polyunsaturated fatty acid oxidation in pre-
term infants without compromising endogenous n-6 long
 
chain polyunsaturated fatty acid synthesis.
 
— Rodriguez, M., S.







































 fatty acid oxidation
 
Preterm infant formulas are considered the best substi-
tute for those premature infants who cannot receive suffi-
cient amounts of human milk. The fat blend of preterm
formulas contains up to 50% medium-chain fatty acids
(8:0, 10:0; MCT) usually contributed by coconut oil (1).
 
They are added to enhance fat and calcium absorption
and to provide the premature infant with a readily avail-
able source of energy (2, 3). In addition, oral lipid supple-
mentation containing a high percentage of MCT was
shown to prevent the occurrence of hypoglycemia in low
birth weight infants (4). In comparison to long-chain tri-
acylglycerols (LCT), MCT are more efficiently absorbed
in the digestive tract, and the liberated medium chain
fatty acids (MCFA) are extensively and rapidly oxidized,
whereas long chain fatty acids (LCFA) are largely stored in
tissues (5). The intense lipid oxidation is associated with a
ketogenic effect of dietary MCT, which provides an alter-
native energy source and is considered harmless for the
infant as long as ketone body concentrations do not ex-
ceed values observed in breast fed infants (5, 6).
Recent studies using stable isotopes have demonstrated
that preterm infants are able to synthesize long-chain
polyunsaturated fatty acids (LCP) such as arachidonic
(20:4n-6) and docosahexaenoic acids (22:6n-3) from their





ids (18:3n-3) (7). Ingestion of MCT is associated with pro-
found changes in plasma fatty acid composition (8, 9), but
the effects of MCT on essential fatty acid and LCP status
are controversial. Wall et al. (10) found significantly lower
tissue levels of arachidonic acid in new-born piglets fed in-
fant formulas containing MCT than in piglets fed formu-




 14:0). In premature in-
fants, an interference of MCT on LCP metabolism was
suggested by Carnielli et al. (9), who reported no effect
on 20:4n-6 concentrations but a decrease in plasma phos-
pholipid 22:6n-3 concentrations after MCT feeding.
 
Abbreviations: AP, atom percent; APE, atom percent excess; LCFA,
long chain fatty acid; LCP, long chain polyunsaturated fatty acids; LCT,
long chain triacylglycerol; MCFA, medium chain fatty acids (8:0–12:0);
MCT, medium chain triacylglycerols (8:0–12:0); MUFA, monounsat-
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On the other hand, the oxidation of MCT in liver creates a
readily available source of reducing equivalents and of car-
bon precursors that could foster elongation of fatty acids
(11). In addition, mRNA concentrations and activities of li-
pogenic enzymes increase with MCT feeding in contrast to
the inhibition seen with LCT feeding (12). Periago et al.
have shown in rats that inclusion of MCT in the diet caused
increased LCP in erythrocyte membrane phospholipids (13).
Adequate brain and tissue levels of 20:4n-6 and 22:6n-3
are important for optimal growth and neuronal develop-
ment, particularly in preterm infants (14, 15). The 20:4n-6
supply has been associated with gain in weight (16) and
body length (17), and 22:6n-3 availability has been associ-
ated with higher scores in cognitive and visual tests (18–22).
Therefore, whether MCT interferes with essential fatty
acid metabolism in infants is of considerable interest. In
the present study, we investigated the effect of dietary MCT
on plasma fatty acid composition, LCP status, and n-6 fatty











37 weeks), but otherwise
healthy infants were enrolled into the study at the Division of Neo-
natology, University of Pécs, Hungary. Inclusion criteria for the
study were birth weight between 1,000 g and 2,000 g, weight ap-
propriate for gestational age (10th to 90th percentile), exclusive
formula feeding with a minimal daily ingestion of 100 ml/kg body
weight, good and stable clinical condition, and no use of intrave-
nous lipid emulsions at the time of enrolment. The study protocol
was approved by the ethical committee, University of Pécs and
written informed consent was obtained from the parents of all in-
fants after detailed description of the study aim and methods.
Infants were randomized to two feeding groups; one received
a formula with 40% (w/w) MCT in dietary fat (MCT group),
whereas the other group was fed a formula with negligible con-




). The omission of MCFA
in the control formula was mainly balanced by palmitic and oleic
acid, but in addition to that, the linoleic acid content was slightly
higher in the control formula (13.15% vs. 11.87%). Contents of
macronutrients (protein, 11.4%; carbohydrates, 39.9%; fat,
46.7% of total energy) and micronutrients were identical in both
groups. The study diet was fed for 7 days. On day 5, after intro-




C-labeled (98%) 18:2n-6 (Martek Bioscience, Columbia, MD)
was given orally to the infants as free fatty acid. The tracer was
dissolved in a small amount of the corresponding formula and




Breath samples were obtained before and at 30-min intervals
after tracer application over a 6 h-period. Using a subnasal prong
connected via a 3-way valve to a 20 ml syringe, exhaled breath
was manually aspirated during the second half of the expiratory
phase and transferred into vacutainers (10 ml, Labco Ltd., Wy-
combe, UK). Samples obtained before the application of labeled














performed by isotope ratio mass spectrometry (23).
Blood samples were obtained before tracer intake on the fifth
study day, and 24 h and 48 h after tracer application. Samples
 
were collected into EDTA-containing tubes. After centrifugation













until analysis. Internal standards [dinonanoyl phosphatidylcholine,
trinonanoin, and nonanoic acid for quantification of MCFA;
dipentadecanoyl phosphatidylcholine, tripentadecanoin, penta-
decanoic acid for quantification of LCFA (Sigma, St Louis, MO)]




l plasma. Lipids were then extracted once
with 2 ml hexane-isopropanol, 4:1 (v/v/v), and twice with 2 ml
hexane, and the pooled extracts were dried under nitrogen and
redissolved in chloroform. Separation of the lipid classes was per-
formed by thin layer chromatography using a mixture of heptane-
isopropanol-acetic acid 60:40:3 (v/v/v) as mobile phase. Lipid
classes (phospholipids, triacylglycerols and free fatty acids) were
transesterified with 2 ml 1.5 M methanolic hydrochloric acid





C for 1 h. After neutralization, distilled water was
added, and the organic phase was transferred into a crimp capped
storage vial. Recoveries of about 90% were obtained for MCFA (data
not shown) by avoiding concentrating the methyl ester solution.
Quantitative analysis of fatty acid methyl esters was performed
with a Hewlett-Packard 5890 series II GC (Hewlett Packard,
Waldbronn, Germany) equipped with an autosampler and a
flame ionization detector. Separation of the individual fatty acids




 0.32 mm BPX 70 column (SGE,
Weiterstadt, Germany) and splitless injection using the given


























C/min until the fi-













C, respectively. Commercial standards
(Sigma; NuChek, Malysian, MN) were used for the identification
of individual fatty acids and the determination of response fac-
tors. In a further aliquot of the fatty acid methyl esters solution





individual fatty acid methyl esters was determined by gas chroma-
tography-combustion-isotope ratio mass spectrometry (delta S,
Finnigan MAT, Bremen, Germany) as previously described (24).




C atom percentage (AP).
 

























Total n-6PUFA 13.28 11.98

























-hydroxybutyrate concentrations were determined








C content above baseline (atom percent excess,
APE %) was obtained by subtracting the basal AP values mea-
sured before tracer application from the AP values measured after
tracer application.






















and n is the number of carbon atoms of the methylated fatty acid









C concentrations in 18:2n-6, 20:3n-6, and 20:4n-6




All statistical calculations were performed with SPSS (SPSS, v.
8.0, Chicago, IL). Since plasma fatty acid concentrations from
study days 5, 6, and 7 were not significantly different, these values
were averaged for each individual and means were used for statis-
tical comparisons between groups. Results are given as means
and standard errors of the mean (SEM). All data were examined
for normality and variance homogeneity before statistical analy-
sis. Differences between the feeding groups were evaluated by













A total of 19 preterm infants participated in the study;
nine infants were assigned to the control group and 10 in-
fants to the MCT group. Infants in the two study groups
presented similar clinical characteristics at birth and at





No adverse effects associated with the ingestion of the two
formulas were observed during the study. Most infants had
received intravenous infusions containing amino acids and
lipids until the 6th day of life, and only one patient had re-
ceived lipid emulsions until the 12th day of life. During
CFA
13 µmol FA∗n∗APE 100⁄=
 
the study period, no infant received intravenous lipid
emulsions. Blood samples from five infants in the control
group and two infants in the MCT group were not ob-





C-enrichment 48 h after tracer ap-
plication was not available in these subjects.
At all measuring points, infants ingesting the control
formula showed higher breath APE values than infants in-





In comparison with the control group, the MCT group

































). The concentrations of all
detected fatty acids (with the exception of oleic acid) in
triacylglycerols were significantly higher or tended to be
higher in the MCT group, but total triacylglycerol fatty
acid concentration was not significantly higher in the
MCT group. Nevertheless, it showed a strong tendency to
do so. The relative distribution of fatty acids was shifted to-
ward significantly higher MCFA and 18:3n-3, while the
percentages of palmitic and oleic acid was significantly
lower in the MCT group.
The significantly higher concentration of total non es-
terified fatty acids was mainly caused by the more than

































), while palmitic, oleic and linoleic acid concentra-
 
TABLE 2. Clinical characteristics [mean (SEM)] of infants at birth 













Gestational age (wk) 30 (0.8) 31 (0.6)
Weight (g) 1370.0 (94.1) 1457.0 (55.0)
Height (cm) 39.4 (0.9) 40.1 (0.6)
Head circumference (cm) 27.8 (0.5) 28.5 (0.2)
Study day 5
Postnatal age (d) 35 (4.6) 35 (4.5)
Weight (g) 1823.3 (88.6) 1913.0 (88.1)
Height (cm) 43.3 (0.5) 44.1 (0.7)
Energy intake (kcal/kg/d) 122.8 (5.1) 137.0 (5.7)













) 17.3 (5.5) 16.1 (3.5)
Tracer ingested (mg/kg) 2.3 (0.1) 2.2 (0.1)
Fig. 1. 13C-atom percent excess values (means  SEM) in
breath CO2 measured over 6 h after tracer application in preterm
infants fed control (black columns) or medium chain triacylglyc-
erols (8:0–12:0) (MCT) (white columns) formula. *P  0.05.















tions were comparable in both groups. Therefore, percent-
age values of most fatty acids with more than 10 carbon
atoms were significantly lower (Table 4).
In contrast to the other fractions, phospholipid fatty acids
hardly differed in their concentrations between groups, as
there was no detectable incorporation of MCFA into phos-
pholipids. Oleic acid percentage was significantly higher in





Ingestion of the formula enriched with MCT was associ-
ated with higher contents of polyunsaturated fatty acids of
both n-6 and n-3 series in the three lipid fractions studied, al-
though the largest differences were observed in the triacyl-




















  0.05) (Tables 3–5).
The plasma concentrations of 	-hydroxybutyrate tended to
be higher in the MCT-group than in the control group
(0.16  0.03 mmol/l vs. 0.08  0.01 mmol/l, not significant).
Figure 2 shows the 13C concentrations (mol/l) in
plasma phospholipid 18:2n-6 and its longer chain metabo-
lites at 24h and at 48h (as available) after tracer administra-
tion. In both groups, plasma phospholipid 18:2n-6 showed
maximal enrichment 24 h after tracer application and de-
creased markedly until 48 h. 13C enrichments in dihomo-
-linolenic acid (20:3n-6) and arachidonic acid (20:4n-6)
increased moderately from baseline to 24 h after tracer ap-
plication, and showed little change until 48 h. The plasma
phospholipid 13C concentrations in mol/l tended to be
lower (not significant) in the MCT group. The ratios be-
tween product (20:4n-6) and precursor (18:2n-6) tracer
concentrations, which indicate conversion intensity toward
n-6 LCP, were similar in both groups 24 h after tracer intake
(0.026  0.005 vs. 0.029  0.005, control vs. MCT) and 48 h
afterwards (0.085  0.013 vs. 0.107  0.016). Furthermore,
there were no significant differences between groups in all
other calculated tracer ratios: 20:3n-6/18:2n-6, 20:4n-6/
TABLE 3. Fatty acid composition of plasma triacylglycerols in preterm infants fed control and MCT formulas











8:0 0.35 (0.12) 2.97 (0.23)b 7.35 (2.09) 93.79 (12.73)b
10:0 0.46 (0.18) 7.03 (0.54)b 9.15 (2.78) 221.50 (29.41)b
12:0 0.07 (0.03) 0.05 (0.01) 1.31 (0.46) 1.48 (0.26)
14:0 1.57 (0.09) 2.25 (0.10)b 37.65 (3.18) 67.55 (6.02)b
16:0 30.81 (0.79) 27.22 (0.75)b 738.38 (42.35) 839.01 (94.81)
17:0 0.17 (0.01) 0.18 (0.01) 4.11 (0.28) 5.36 (0.52)
18:0 3.20 (0.21) 3.67 (0.11) 75.09 (4.00) 112.21 (11.79)b
20:0 0.20 (0.01) 0.21 (0.01) 4.60 (0.25) 6.22 (0.59)a
22:0 0.06 (0.01) 0.08 (0.01)a 1.36 (0.11) 2.48 (0.33)b
 SFA 36.88 (1.04) 43.66 (1.28)b 879.00 (47.68) 1349.61 (148.95)a
Monounsaturated fatty acids
14:1n-5 0.11 (0.01) 0.16 (0.01)a 2.56 (0.13) 4.47 (0.26)b
16:1n-7 2.64 (0.39) 3.69 (0.55) 65.07 (11.26) 106.82 (14.41)a
18:1n-9 42.85 (0.66) 32.85 (0.63)b 1030.58 (71.44) 1004.04 (107.36)
18:1n-7 1.89 (0.17) 2.22 (0.21) 46.08 (5.68) 65.17 (6.07)a
20:1n-9 0.40 (0.01) 0.45 (0.02)a 9.78 (0.78) 13.71 (1.31)a
 MUFA 47.90 (0.95) 39.37 (1.03)b 1154.07 (84.77) 1194.21 (115.67)
Polyunsaturated fatty acids
20:3n-9 0.20 (0.02) 0.31 (0.05) 4.84 (0.64) 8.59 (0.83)b
n-6 PUFA
18:2n-6 12.41 (0.13) 13.28 (1.06) 296.79 (16.18) 411.31 (57.98)
18:3n-6 0.22 (0.02) 0.27 (0.02) 5.39 (0.71) 7.50 (0.38)
20:2n-6 0.17 (0.01) 0.25 (0.02)b 3.99 (0.32) 7.66 (1.08)b
20:3n-6 0.22 (0.02) 0.21 (0.02) 5.15 (0.51) 6.18 (0.65)
20:4n-6 0.49 (0.06) 0.54 (0.05) 11.83 (1.59) 15.49 (1.24)
22:4n-6 0.11 (0.01) 0.14 (0.01) 2.59 (0.43) 3.98 (0.31)a
22:5n-6 0.15 (0.02) 0.22 (0.03)a 3.57 (0.58) 6.53 (0.81)a
n-6 PUFA 13.77 (0.17) 14.91 (1.10) 329.29 (18.93) 458.65 (60.85)
n-6 LCP 1.13 (0.11) 1.36 (0.11) 27.12 (3.33) 39.84 (3.62)a
n-3 PUFA
18:3n-3 0.75 (0.03) 1.05 (0.08)b 17.73 (0.82) 33.32 (5.10)a
20:5n-3 0.05 (0.00) 0.08 (0.01)b 1.14 (0.14) 2.28 (0.08)b
22:5n-3 0.08 (0.01) 0.08 (0.01) 1.90 (0.31) 2.50 (0.28)
22:6n-3 0.12 (0.02) 0.13 (0.01) 2.94 (0.48) 3.86 (0.43)
n-3 PUFA 0.99 (0.03) 1.35 (0.08)b 23.70 (1.20) 41.96 (5.68)b
n-3 LCP 0.25 (0.03) 0.30 (0.02) 5.97 (0.86) 8.64 (0.72)a
 PUFA 14.96 (0.20) 16.57 (1.16)a 357.83 (20.54) 509.20 (65.95)
 LCP 1.59 (0.16) 1.97 (0.16) 37.93 (4.75) 57.07 (4.36)a
 fatty acids 2396.61 (144.75) 3064.75 (312.93)
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; LCP, long-
chain polyunsaturated fatty acids. Values are means and SEM. 
a P  0.05.
b P  0.01.
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20:3n-6 and (20:3n-620:4n-6)/18:2n-6. All product/pre-
cursor ratios were higher at 48 h than at 24 h after intake.
DISCUSSION
The significantly lower APE values of exhaled CO2 in
the MCT group indicate that the exogenously applied 13C-
labeled 18:2n-6 contributed less to total substrate oxida-
tion in the MCT group than in the LCT group during the
postprandial phase. Liet et al. demonstrated that total
CO2 production is not significantly different between pre-
term neonates fed parenterally with an LCT or an MCT/
LCT emulsion (25). As the 18:2n-6 content was slightly
lower in the MCT formula, a higher dilution of the tracer
within the diet can be excluded. Thus, one explanation
for the difference in 13CO2 enrichment is a lower 18:2n-6
oxidation rate in the MCT group. On the other hand, tri-
acylglycerol bound 18:2n-6 was about one third higher in
the MCT group, causing a higher dilution of the ingested
tracer in the present pool of 18:2n-6 and as a consequence
less tracer was oxidized. Both explanations are in agree-
ment, as relatively less oxidation of dietary 18:2n-6 leads to
higher plasma concentrations, which by itself decreases
trace recovery in breath. Differences in intestinal tracer
absorption are not expected as similar percentage absorp-
tion of individual fatty acids have been reported in infants
receiving formulas providing fat as LCT or as MCT (26),
and it can reasonably be assumed that 13C-labeled 18:2n-6
was efficiently absorbed in both groups. Preferential
MCFA oxidation by the liver in the postprandial phase in-
fluences 18:2n-6 oxidation in infants fed the formula with
MCT. After absorption, LCFA are mostly reesterified into
triacylglycerols in the intestinal epithelial cells to form
chylomicrons that are transported via the lymph and
taken to all tissues, whereas MCFA are largely transported
via the portal vein and reach the liver as the first organ
perfused. In the hepatocyte, LCFA are preferentially acti-
vated in the cytosol and incorporated into triacylglycerols
and phospholipids, and only a small proportion enters the
mitochondria via the carnitine acyltransferase system. On
the other hand, MCFA may enter the mitochondria par-
tially independent from carnitine and are largely oxidized
(5). It has been shown that during MCT ingestion the car-
nitine palmitoyltransferase is inhibited, consequently oxi-
dation of LCFA is reduced and their incorporation into
complex lipids enhanced (27). These metabolic differ-
ences between MCT and LCT explain why in preterm in-
fants fed a high MCT diet, the preferential oxidation of
MCFA causes a decrease in 18:2n-6 oxidation.
Although the oxidation rate of MCFA is much higher than
that of LCFA (28), the study by Sulkers et al. (29) shows that
about half of the ingested MCT follows pathways other than
oxidation. Among these, urinary loss of dicarboxylic acids,
TABLE 4. Fatty acid composition of plasma non esterified fatty acids in preterm infants fed control and 
MCT formulas











8:0 8.78 (1.41) 23.77 (1.92)b 21.48 (3.91) 98.04 (13.29)
10:0 12.46 (0.73) 21.69 (0.85)b 29.90 (2.63) 83.99 (6.83)b
12:0 0.16 (0.01) 0.16 (0.02) 0.38 (0.04) 0.62 (0.12)
14:0 1.85 (0.06) 1.63 (0.08) 4.46 (0.24) 6.32 (0.83)b
16:0 31.31 (0.59) 22.89 (1.02)b 76.33 (4.53) 88.18 (10.44)
18:0 9.04 (0.44) 6.57 (0.33)b 21.64 (1.03) 25.28 (3.27)
 SFA 63.60 (1.16) 76.70 (1.33)b 154.20 (9.21) 302.43 (29.50)b
Monounsaturated fatty acids
16:1n-7 1.09 (0.12) 0.88 (0.11) 2.66 (0.30) 3.23 (0.35)
18:1n-9 21.70 (0.96) 11.52 (0.77)b 53.51 (3.97) 43.70 (4.12)
18:1n-7 0.89 (0.06) 0.69 (0.06)a 2.19 (0.19) 2.60 (0.27)
20:1n-9 2.44 (0.19) 2.35 (0.21) 5.80 (0.53) 8.88 (1.34)a
 MUFA 26.12 (0.88) 15.44 (0.78)b 64.16 (4.38) 58.41 (5.37)
Polyunsaturated fatty acids
n-6 PUFA
18:2n-6 7.92 (0.48) 5.95 (0.53)a 19.33 (1.51) 22.74 (2.68)
20:3n-6 0.47 (0.05) 0.36 (0.03) 1.11 (0.11) 1.36 (0.15)
20:4n-6 0.96 (0.11) 0.68 (0.09)a 2.27 (0.23) 2.51 (0.29)
n-6 PUFA 9.35 (0.60) 6.99 (0.54)a 22.71 (1.69) 26.62 (2.88)
n-6 LCP 1.43 (0.16) 1.04 (0.10)a 3.38 (0.33) 3.88 (0.36)
n-3 PUFA
18:3n-3 0.39 (0.02) 0.36 (0.03) 0.96 (0.08) 1.38 (0.14)a
n-3 PUFA 0.39 (0.02) 0.36 (0.03) 0.96 (0.08) 1.38 (0.14)a
 PUFA 9.74 (0.61) 7.35 (0.57)a 23.67 (1.74) 28.00 (3.00)
 LCP 1.43 (0.16) 1.04 (0.10)a 3.38 (0.33) 3.88 (0.36)
 fatty acids 100.00 (0.00) 100.00 (0.00) 243.35 (13.20) 390.87 (36.45)b
Values are means and SEM. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsatu-
rated fatty acids; LCP, long-chain polyunsaturated fatty acids.
a P  0.05.










46 Journal of Lipid Research Volume 44, 2003
storage in adipose tissue, and conversion to LCFA has been
described (11, 27, 30). We observed a trend toward higher
	-hydroxybutyrate plasma levels in the MCT group, with con-
centrations similar to previous observations in neonates fed
formula or breast milk (31, 32, 33).
Relatively high proportions of 8:0 and 10:0 are incorpo-
rated into plasma triacylglycerols. The percentages of
MCFA found in our study after MCT feeding are similar to
those reported by Carnielli et al. (9). Although dietary
MCFA are largely transported via the portal vein, the si-
multaneous ingestion of MCT and LCT may enable the
lymphatic transport of MCFA (34, 35). In the present
study, 8:0 was the predominant MCFA in the diet, but
there was three times more 10:0 than 8:0 in plasma tri-
acylglycerols of the infants, suggesting a decreased ten-
dency toward oxidation or an increased tendency toward
incorporation into triacylglycerols with increasing carbon
chain length (36). Furthermore, during MCT feeding the
oxidation capacity for MCFA by the liver might be ex-
ceeded, resulting in incomplete hepatic clearance of di-
etary MCFA. The production of 13CO2 after a constant
infusion of 13C-labeled octanoate to preterm infants
reached a plateau within 1–3 h, thus indicating that the
amount of MCT that can be oxidized by the liver is limited
(29). Hence, MCFA not metabolized by the liver may be
incorporated into VLDL-triacylglycerols by the liver, or
they may remain in blood as nonesterified fatty acids. The
higher concentration of non esterified fatty acids in the
MCT group is almost completely explained by the higher
8:0 and 10:0 concentrations and as a consequence, the
percentage distribution changes. Furthermore, MCFA
present in plasma might have been released from adipose
tissue, since infants fed MCT formulas may store up to
12% of 8:0 and 10:0 in adipose tissue (37).
TABLE 5. Fatty acid composition of plasma phospholipids in preterm infants fed control and MCT formulas











12:0 0.04 (0.01) 0.04 (0.01) 1.23 (0.17) 1.15 (0.21)
14:0 0.26 (0.02) 0.34 (0.02)a 8.01 (0.75) 11.11 (1.11)
16:0 29.83 (0.33) 29.90 (0.65) 937.30 (40.19) 961.16 (56.76)
17:0 0.28 (0.01) 0.31 (0.01) 8.78 (0.23) 9.83 (0.54)
18:0 15.59 (0.28) 16.12 (0.36) 487.90 (18.18) 516.74 (30.89)
20:0 0.77 (0.03) 0.77 (0.02) 24.35 (1.38) 24.71 (1.20)
22:0 1.13 (0.06) 1.19 (0.05) 35.38 (1.94) 37.85 (1.93)
24:0 0.92 (0.04) 1.03 (0.05) 28.98 (1.64) 32.59 (1.79)
 SFA 48.83 (0.35) 49.70 (0.55) 1531.94 (59.76) 1595.12 (87.34)
Monounsaturated fatty acids
16:1n-7 0.47 (0.05) 0.63 (0.13) 15.01 (2.24) 20.80 (4.94)
18:1n-9 12.60 (0.20) 10.73 (0.37)b 396.66 (20.72) 346.02 (24.29)
18:1n-7 1.66 (0.12) 1.75 (0.16) 53.27 (5.89) 56.61 (6.69)
20:1n-9 0.34 (0.02) 0.36 (0.03) 10.80 (0.82) 11.89 (1.63)
24:1n-9 2.44 (0.19) 2.49 (0.15) 78.43 (9.62) 79.17 (5.39)
 MUFA 17.51 (0.41) 15.96 (0.71)a 554.18 (37.20) 514.50 (39.39)
Polyunsaturated fatty acids
20:3n-9 0.39 (0.03) 0.65 (0.17) 12.37 (1.28) 21.65 (6.19)
n-6 PUFA
18:2n-6 19.49 (0.57) 19.58 (1.08) 609.51 (24.10) 622.06 (38.51)
18:3n-6 0.15 (0.02) 0.17 (0.02) 4.84 (0.52) 5.73 (0.99)
20:2n-6 0.40 (0.02) 0.56 (0.03) 12.57 (0.89) 18.17 (1.85)a
20:3n-6 2.90 (0.13) 2.56 (0.15) 91.25 (6.20) 83.23 (7.76)
20:4n-6 6.61 (0.33) 6.77 (0.31) 208.96 (16.56) 218.78 (16.90)
22:2n-6 0.47 (0.04) 0.51 (0.05) 14.67 (1.01) 15.77 (1.47)
22:4n-6 0.40 (0.02) 0.41 (0.03) 12.83 (1.10) 13.66 (1.61)
22:5n-6 0.43 (0.03) 0.56 (0.04)a 13.41 (1.10) 18.60 (2.07)a
n-6 PUFA 30.85 (0.33) 31.13 (0.88) 968.03 (39.61) 996.00 (53.66)
n-6 LCP 11.21 (0.39) 11.38 (0.42) 353.68 (23.75) 368.21 (27.49)
n-3 PUFA
18:3n-3 0.10 (0.00) 0.15 (0.01)b 3.06 (0.18) 4.95 (0.50)b
20:3n-3 0.05 (0.00) 0.06 (0.01)a 1.59 (0.10) 2.11 (0.24)
20:5n-3 0.19 (0.02) 0.32 (0.03)b 5.96 (0.84) 10.35 (1.34)a
22:5n-3 0.30 (0.02) 0.31 (0.02) 9.52 (0.91) 10.17 (1.00)
22:6n-3 1.50 (0.13) 1.36 (0.06) 47.63 (5.58) 43.90 (3.38)
n-3 PUFA 2.13 (0.14) 2.21 (0.07) 67.75 (6.75) 71.49 (5.28)
n-3 LCP 2.03 (0.15) 2.05 (0.06) 64.70 (6.69) 66.54 (4.88)
 PUFA 33.37 (0.31) 33.98 (0.75) 1048.15 (45.75) 1089.14 (58.37)
 LCP 13.63 (0.54) 14.08 (0.49) 430.75 (31.20) 456.40 (34.21)
 fatty acids 100.00 (0.00) 100.00 (0.00) 3143.38 (140.64) 3210.34 (169.38)
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; LCP, long-
chain polyunsaturated fatty acids. Values are means and SEM. 
a P  0.05.
b P  0.01.
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Concentrations of LCFA in plasma triacylglycerols of
the two feeding groups were similar, although dietary in-
take of 16:0, 18:0, and 18:1 in the MCT group was almost
50% lower than in the control group (Table 1). Although
triacylglycerols tend to reflect the dietary fatty acid pat-
tern, no decrease in 16:0 was observed, and absolute
amounts of other saturated fatty acids such as 14:0, 18:0,
20:0, 22:0, and 24:0 even increased. Absolute concentra-
tions of 18:1n-9 in plasma triacylglycerols did not differ
between groups, despite the low amount present in the
MCT formula. Thus, the higher percentage of MCFA was
largely compensated for by decreased 18:1n-9 percent-
ages, as concentrations of polyunsaturated fatty acids also
tended to be higher with the MCT diet. The high concen-
trations of saturated fatty acids and partly 18:1n-9 in the
MCT group might have been caused by increased hepatic
fatty acid synthesis either de novo, or by chain elongation,
as suggested first in adults (8) and later in preterm infants
with a high intake of MCT (38). Another factor explain-
ing the increased plasma LCFA concentrations in MCT
fed infants is the preferential oxidation of MCFA by the
liver, which may preserve LCFA from oxidation (27). The
observed concentration differences are in line with both
explanations, as 18:1n-9 tends to be oxidized preferentially
compared with palmitic acid (39). However, only reduced
LCFA oxidation can explain the higher plasma concentra-
tions of 18:2n-6 and 18:3n-3, which were fed in equal amounts
with both diets. Furthermore, in triacylglycerols the MCT
group presented higher concentrations of 20:2n-6, 22:4n-6,
22:5n-6, and 20:5n-3 than the control group (P  0.05),
which could also be due to reduced LCP oxidation.
Total triacylglycerol bound fatty acids were 28% higher in
the MCT fed group than in the control group, although the
difference was not statistically significant. This is in accor-
dance with the reported 3-fold increase in fasting serum tri-
acylglycerol concentrations (8) and enhanced secretion of
VLDL by the liver (40) after MCT feeding.
In contrast to Carnielli et al. (9), we observed higher
absolute and relative concentrations of 18:3n-3, 20:5n-3,
20:2n-6, and 22:5n-6 in plasma phospholipids of MCT fed
infants, while we did not see lower values of 22:6n-3. The
differences might be explained by the higher postnatal
age of the infants or the shorter duration of intervention
in our study. Compared with the influence of the MCT
diet on triacylglycerols, the effects on plasma phospholip-
ids are small. The concentrations of 13C-labeled 18:2n-6
and its metabolites in phospholipids tended to be lower in
the infants fed the MCT formula particularly at 48 h after
tracer administration, although in this group tracer oxida-
tion seemed to be lower. This corresponds to the larger
pool size of polyunsaturated fatty acids in the MCT group
(especially triacylglycerols) and thus more dilution of the
tracer before incorporation into plasma phospholipids
whose concentrations changed only marginally.
It has been shown that term and preterm infants are
able to synthesize both 20:4n-6 and 22:6n-3 from their pre-
cursor fatty acids (21, 23). In the present study, determi-
nations of 13C excess in plasma phospholipid n-6 fatty ac-
ids allowed us to study 18:2n-6 metabolism in the two
feeding groups. Since MCT feeding produces a slight hy-
perinsulinemic response (41, 42), it might enhance 5
and 6 desaturase activity (43). However, the ratios of 13C
enrichments and tracer concentrations of precursor and
product fatty acids were similar between the feeding
groups, indicating no influence of MCT on the fractional
conversion of 18:2n-6 toward LCP.
Oxidation of all LCP (including 18:2n-6, 20:3n-6, and
20:4n-6) might have been reduced by MCT, similar to the ef-
fects on 18:2n-6 oxidation. No data on LCP oxidation in in-
fants have been published, although experiments in animals
have shown that dietary LCP are preferentially channeled
into structural lipids (44) and are only oxidized to a limited
extent (36). Nevertheless, preservation of LCP from oxida-
tion might increase their concentrations in plasma lipids.
As MCT seems to decrease oxidation of 18:2n-6 and not
to influence relative conversion rates, it might enhance ab-
solute conversion of 18:2n-6 into LCP in situations when
18:2n-6 availability is limiting LCP synthesis. Although we
did not measure 13C excess in phospholipid n-3 fatty acids,
the same hypothesis and approaches as for n-6 series would
be valid to explain an influence of MCT on the concentra-
tion of n-3 polyunsaturated fatty acids, excluding a potential
influence of high MCFA concentrations on peroxisomal
chain shortening, which is required for 22:6n-3 synthesis (7)
In conclusion, our results show that feeding preterm in-
fants with an infant formula providing 40% of total fatty
acids as MCFA results in lower 18:2n-6 oxidation without
affecting relative conversion of 18:2n-6 to longer chain me-
tabolites. This spares essential fatty acids from oxidation.
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Fig. 2. 13C-concentration (mol 13C/l, mean  SEM) in plasma
phospholipid n-6 fatty acids in preterm infants fed control or MCT
formulas 24 h and 48 h after tracer application (black columns, MCT
group; white columns, control group), no significant differences be-
tween groups, but all values are significantly different from 0.
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